DOCSLIB.ORG

Lääkeluettelon Aineet, Liite 1. Ämnena I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lääkeluettelon Aineet, Liite 1. Ämnena I LÄÄKELUETTELON AINEET, LIITE 1. 1 ÄMNENA I LÄKEMEDELSFOÖRTECKNINGEN, BILAGA 1. Suomenkielinen nimi, Latinankielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Finskt namn Latinskt namn Svenskt namn Engelskt namn (N)-Hydroksietyyli- (N)-Hydroxy- (N)-Hydroxietyl-prometazin (N)-Hydroxyethyl- prometatsiini aethylprometazinum promethazine 2,4-Diklooribentsyyli- 2,4-Dichlorbenzyl-alcoholum 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcohol alkoholi 2-Isopropoksifenyyli-N- 2-Isopropoxyphenyl-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- metyylikarbamaatti methylcarbamas metylkarbamat methylcarbamate 4-Dimetyyliaminofenoli 4-Dimethyl- aminophenolum 4-Dimetylaminofenol 4-Dimethylaminophenol 6,7-diF-1-MeTIQ 6,7-diF-1-MeTIQ 6,7-diF-1-MeTIQ 6,7-diF-1-MeTIQ Abakaviiri Abacavirum Abakavir Abacavir Abareliksi Abarelixum Abarelix Abarelix Abatasepti Abataceptum Abatacept Abatacept Abirateroni Abirateronum Abirateron Abiraterone Absiksimabi Abciximabum Absiximab Abciximab Adalimumabi Adalimumabum Adalimumab Adalimumab Adapaleeni Adapalenum Adapalen Adapalene Adefoviiridipivoksiili Adefovirum dipivoxilum Adefovirdipivoxil Adefovir dipivoxil Ademetioniini Ademetioninum Ademetionin Ademetionine Adenosiini Adenosinum Adenocin Adenosine Adinatsolaamimesilaatti Adinazolami mesilas Adinazolammesilat Adinazolam mesilate Adipiodoni Adipiodonum Adipiodon Adipiodone Adrafiniili Adrafinilum Adrafinil Adrafinil Adrenaliini Adrenalinum Adrenalin Adrenaline Adrenaliinitartraatti Adrenalini tartras Adrenalintartrat Adrenaline tartrate Adrenaloni Adrenalonum Adrenalon Adrenalone Afamelanotidi Afamelanotidum Afamelanotid Afamelanotide Afatinibi Afatinibum Afatinib Afatinib Aflibersepti Afliberceptum Aflibercept Aflibercept Afobatsoli Afobazolum Afobazol Afobazole Afoksolaneeri Afoxolanerum Afoxolaner Afoxolaner Agalsidaasi Agalsidasum Agalsidas Agalsidase Aglepristoni Aglepristonum Aglepriston Aglepristone Agomelatiini Agomelatinum Agomelatin Agomelatine Aimaliini Ajmalinum Ajmalin Ajmaline Akamprosaatti Acamprosatum Acamprosat Acamprosate Akarboosi Acarbosum Akarbos Acarbose Aklarubisiini Aclarubicinum Aklarubicin Aclarubicin Aklidinium Aclidinium Aclidinium Aclidinium Akrivastiini Acrivastinum Acrivastin Acrivastine Aksitinibi Axitinibum Axitinib Axitinib Alaproklaatti Alaproclatum Alaproklat Alaproclate Alatrofloksasiini Alatrofloxacinum Alatrofloxacin Alatrofloxacin Albendatsoli Albendazolum Albendazol Albendazole Albiglutidi Albiglutidum Albiglutid Albiglutide Albumiini, ihmisen Albuminum humanum Albumin Albumin, human Albumiinitannaatti Albumini tannas Albumintannat Albumin tannate Aldesleukiini Aldesleukinum Aldesleukin Aldesleukin Aldesulfoninatrium Aldesulfonum natricum Aldesulfonnatrium Aldesulfone sodium Aldosteroni Aldosteronum Aldosteron Aldosterone Lausuntokierros -Liite-1-8-10-2018-Laakeluettelo-FIMEA LÄÄKELUETTELON AINEET, LIITE 1. 2 ÄMNENA I LÄKEMEDELSFOÖRTECKNINGEN, BILAGA 1. Alektinibi Alectinibum Alektinib Alectinib uusi Alemtutsumabi Alemtuzumabum Alemtuzumab Alemtuzumab Alendronihappo Acidum alendronicum Alendronsyra Alendronic acid Alfakalsidoli Alfacalcidolum Alfakalcidol Alfacalcidol Alfaksaloni Alfaxalonum Alfaxalon Alfaxalone; alphaxalone Alfentaniili Alfentanilum Alfentanil Alfentanil Alfutsosiini Alfuzosinum Alfuzosin Alfuzosin Algeldraatti Algeldratum Algeldrat Algeldrate Algiinihappo Acidum alginicum Alginsyra Alginic acid Alglukosidaasialfa Alglucosidase alfa Alglukosidas alfa Alglucosidase alfa Alimematsiini Alimemazinum Alimemazin Alimemazine Aliskireenifumaraatti Aliskireni fumaras Aliskirenfumarat Aliskiren fumarate Alitretinoiini Alitretinoinum Alitretinoin Alitretinoin Alklofenaakki Alclofenacum Alklofenak Alclofenac Alklometasonidipropionaatti Alclometasoni dipropionas Alklometason-dipropionat Alclometasone dipropionate Alkuroniumkloridi Alcuronii chloridum Alkuroniumklorid Alcuronium chloride Allobarbitaali Allobarbitalum Allobarbital Allobarbital Allopurinoli Allopurinolum Allopurinol Allopurinol Allyyliestrenoli Allylestrenolum Allylestrenol Allylestrenol Almitriini Almitrinum Almitrin Almitrine Almotriptaani Almotriptanium Almotriptan Almotriptan Alogliptiini Alogliptinum Alogliptin Alogliptin Aloksipriini Aloxiprinum Aloxiprin Aloxiprin Alpratsolaami Alprazolamum Alprazolam Alprazolam Alprenololi Alprenololum Alprenolol Alprenolol Alprostadiili Alprostadilum Alprostadil Alprostadil Alteplaasi Alteplasum Alteplas Alteplase Altrenogesti Altrenogestum Altrenogest Altrenogest Altretamiini Altretaminum Altretamin Altretamine Aluminiumasetotartraatti Aluminii acetotartras Aluminiumacetotartrat Aluminium acetotartrate Aluminiumklofibraatti Aluminii clofibras Aluminiumklofibrat Aluminium clofibrate Alveriini Alverinum Alverin Alverine Amantadiini Amantadinum Amantadin Amantadine Ambatsoni Ambazonum Ambazon Ambazone Ambenonium Ambenonium Ambenonium Ambenonium Ambenoniumkloridi Ambenonii chloridum Ambenoniumklorid Ambenonium chloride Ambrisentaani Ambrisentanum Ambrisentan Ambrisentan Ambroksoli Ambroxolum Ambroxol Ambroxol Ambroksolihydrokloridi Ambroxoli hydrochloridum Ambroxolhydroklorid Ambroxol hydrochloride Ambutoniumbromidi Ambutonii bromidum Ambutoniumbromid Ambutonium bromide Ametsiniummetilsulfaatti Amezinii metilsulfas Ameziniummetilsulfat Amezinium metilsulfate Amfepramoni Amfepramonum Amfepramon Amfepramone Amfetamiini Amphetaminum Amfetamin Amphetamine; amfetamine Amfetaminiili Amfetaminilum Amfetaminil Amfetaminil uusi Amfoterisiini Amphotericinum Amfotericin Amphotericin Amifampridiini Amifampridinum Amifampridin Amifampridine Amifostiini Amifostinum Amifostin Amifostine Amikasiini Amikacinum Amikacin Amikacin Amiloridi Amiloridum Amilorid Amiloride Aminoakridiini Aminoacridinum Aminoakridin Aminoacridine Lausuntokierros -Liite-1-8-10-2018-Laakeluettelo-FIMEA LÄÄKELUETTELON AINEET, LIITE 1. 3 ÄMNENA I LÄKEMEDELSFOÖRTECKNINGEN, BILAGA 1. Aminoetikkahappo (glysiini) Acidum aminoaceticum Aminoättiksyra (glycin) Aminoacetic acid Aminofenatsoni Aminophenazonum Aminofenazon Aminophenazone Aminofylliini Aminophyllinum Aminofyllin Aminophylline Aminoglutetimidi Aminoglutethimidum Aminoglutetimid Aminoglutethimide Aminohippurihappo Acidum aminohippuricum Aminohippursyra Aminohippuric acid Aminokapronihappo Acidum aminocaproicum Aminokapronsyra Aminocaproic acid Aminokinuridi Aminoquinuridum Aminokinurid Aminoquinuride Aminolevuliinihappo Acidum aminolevulicum Aminolevulinsyra Aminolevulinic acid Aminonitrotiatsoli Aminonitrothiazolum Aminonitrotiazol Aminonitrothiazole Aminosalisyylihappo Acidum aminosalicylicum Aminosalicylsyra Aminosalisylic acid Aminosalyylikalsium Aminosalylcalcium Aminosalylkalcium Aminosalicylate calcium Aminovaleriaanahappo Acidum aminovalericum Aminovaleriansyra Aminovaleric acid Amiodaroni Amiodaronum Amiodaron Amiodarone Amisulpridi Amisulpridum Amisulprid Amisulpride Amitratsi Amitrazum Amitraz Amitraz Amitriptyliini Amitriptylinum Amitriptylin Amitriptyline Amleksanoksi Amlexanoxum Amlexanox Amlexanox Amlodipiini Amlodipinum Amlodipin Amlodipine Ammoniumkloridi Ammonium chloridum Ammoniumklorid Ammonium Chloride Amobarbitaali Amobarbitalum Amobarbital Amobarbital Amoksapiini Amoxapinum Amoxapin Amoxapine Amoksisilliini Amoxicillinum Amoxicillin Amoxicillin Amorolfiini Amorolfinum Amorolfin Amorolfine Amperotsidihydrokloridi Amperozidi hydrochloridum Amperozidhydroklorid Amperozide hydrochloride Ampisilliini Ampicillinum Ampicillin Ampicillin Amprenaviiri Amprenavirum Amprenavir Amprenavir Amrinoni Amrinonum Amrinon Amrinone Amsakriini Amsacrinum Amsakrin Amsacrine Amyylimetakresoli Amylmetacresolum Amylmetakresol Amylmetacresol Amyylinitriitti Amyli nitris Amylnitrit Amyl nitrite Anagrelidi Anagrelinum Anagrelid Anagrelide Anakinra Anakinrum Anakinra Anakinra Anastrotsoli Anastrozolum Anastrozol Anastrozole Androsta-1,4,6-trieeni-3,17- Androsta-1,4,6-triene-3,17- Androsta-1,4,6-triene-3,17- Androsta-1,4,6-triene-3,17- dioni (ATD) dione (ATD) dione (ATD) dione (ATD) Androstanoloni Androstanolonum Androstanolon Androstanolone Anestesiaeetteri, Aether anaestheticus Narkoseter Ether, anaesthetic narkoosieetteri Angiotensiiniamidi Angiotensinamidum Angiotensinamid Angiotensinamide Anidulafungiini Anidulafunginum Anidulafungin Anidulafungin Anileridiini Anileridinum Anileridin Anileridine Anirasetaami Aniracetamum Aniracetam Aniracetam Anistreplaasi Anistreplasum Anistreplas Anistreplase Ankroni Ancronum Ankron Ancron Ansamysiini Ansamycinum Ansamycin Ansamycin Antatsoliini Antazolinum Antazolin Antazoline Antitrombiini Antithrombinum Antitrombin Antithrombin Apiksabaani Apixabanum Apixaban Apixaban Apomorfiini Apomorphinum Apomorfin Apomorphine Apomorfiinihydrokloridi Apomorphini hydrochloridum Apomorfinhydroklorid Apomorphine hydrochloride Apraklonidiini Apraclonidinum Apraklonidin Apraclonidine Apramysiinisulfaatti Apramycini sulfas Apramycinsulfat Apramycin sulfate Apremilasti Apremilastum Apremilast Apremilast Aprepitantti Aprepitantum Aprepitant Aprepitant Lausuntokierros -Liite-1-8-10-2018-Laakeluettelo-FIMEA LÄÄKELUETTELON AINEET, LIITE 1. 4 ÄMNENA I LÄKEMEDELSFOÖRTECKNINGEN, BILAGA 1. Aprindiini Aprindinum Aprindin Aprindine Aprobarbitaali Aprobarbitalum Aprobarbital Aprobarbital Apronaali Apronalum Apronal Apronal Aprotiniini Aprotininum Aprotinin Aprotinin Arekoliinihydrobromidi Arecolini hydrobromidum Arekolinhydrobromid Arecoline hydrobromide Argatrobaani Argatrobanum Argatropan Argatroban Argipressiini Argipressinum Argipressin Argipressin Arimistaani Arimistanum Arimistane Arimistane uusi Aripipratsoli Aripiprazolum Aripiprazol Aripiprazole Arseenitrioksidi Arseni trioxydum
Load more

Recommended publications
  • Fosaprepitant Dimeglumine (Emend® for Injection) Prior Authorization Drug Coverage Policy
    1 Fosaprepitant dimeglumine (Emend® for injection) Prior Authorization Drug Coverage Policy Effective Date: 9/1/2020 Revision Date: n/a Review Date: 3/13/20 Lines of Business: Commercial Policy type: Prior Authorization This Drug Coverage Policy provides parameters for the coverage of fosaprepitant dimeglumine. Consideration of medically necessary indications are based upon U.S. Food and Drug Administration (FDA) indications, recommended uses within the Centers of Medicare & Medicaid Services (CMS) five recognized compendia, including the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium (Category 1 or 2A recommendations), and peer-reviewed scientific literature eligible for coverage according to the CMS, Medicare Benefit Policy Manual, Chapter 15, section 50.4.5 titled, “Off-Label Use of Anti-Cancer Drugs and Biologics.” This policy evaluates whether the drug therapy is proven to be effective based on published evidence-based medicine. Drug Description 1 Fosaprepitant is a prodrug of aprepitant and accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin- induced emesis.
    [Show full text]
  • MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
    1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated.
    [Show full text]
  • Arecoline Promotes Migration of A549 Lung Cancer Cells Through Activating the EGFR/Src/FAK Pathway
    toxins Article Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway Chih-Hsiang Chang 1,†, Mei-Chih Chen 2,3,†, Te-Huan Chiu 1 , Yu-Hsuan Li 1, Wan-Chen Yu 1, Wan-Ling Liao 1, Muhammet Oner 1, Chang-Tze Ricky Yu 4, Chun-Chi Wu 5, Tsung-Ying Yang 6, Chieh-Lin Jerry Teng 7, Kun-Yuan Chiu 8, Kun-Chien Chen 6, Hsin-Yi Wang 9, Chia-Herng Yue 10, Chih-Ho Lai 11 , Jer-Tsong Hsieh 12 and Ho Lin 1,13,14,* 1 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan; [email protected] (C.-H.C.); [email protected] (T.-H.C.); [email protected] (Y.-H.L.); [email protected] (W.-C.Y.); [email protected] (W.-L.L.); [email protected] (M.O.) 2 Medical Center for Exosomes and Mitochondria Related Diseases, China Medical University Hospital, Taichung 40447, Taiwan; [email protected] 3 Department of Nursing, Asia University, Taichung 41345, Taiwan 4 Department of Applied Chemistry, National Chi Nan University, Nantou 54561, Taiwan; [email protected] 5 Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan; [email protected] 6 Division of Chest Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] (T.-Y.Y.); [email protected] (K.-C.C.) 7 Division of Hematology/Medical Oncology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 8 Division of Urology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 9 Department of Nuclear Medicine, Taichung
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Deciphering Emesis
    International Journal of Pharmaceutical Chemistry and Analysis 2021;8(1):19–24 Content available at: https://www.ipinnovative.com/open-access-journals International Journal of Pharmaceutical Chemistry and Analysis Journal homepage: https://www.ijpca.org/ Review Article Deciphering emesis 1, 2 Sunil Chaudhry *, Avisek Dutta 1Bioclinitech Technologies Pvt Ltd, Mumbai & GPATTutor.com,, India 2Cognizant Aolutions, Kolkata, West Bengal, India ARTICLEINFO ABSTRACT Article history: The incidence of nausea or vomiting changes much with etiopathogenesis. Multiple neurohumoural Received 04-03-2021 pathways lead to nausea and vomiting. The various classes of antiemetics target different pro-emetic Accepted 09-03-2021 pathways to alleviate nausea and vomiting. Some drugs target more than one pathway. It is demonstrated Available online 04-05-2021 that combination therapy is more effective than single anti-emetic agent. © This is an open access article distributed under the terms of the Creative Commons Attribution Keywords: License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and Vomiting reproduction in any medium, provided the original author and source are credited. Chemoreceptor trigger zone Aprepitant Cannabinoid receptor agonist 5 HT receptor antagonist Neurokinin receptor antagonists 1. Introduction 5. Refractory: Nausea and/or vomiting that occurs in subsequent chemotherapy cycles despite maximum Vomiting or emesis, is defined as the involuntary, forceful antiemetic protocol expulsion of the contents of stomach through the mouth and 6. Anticipatory: Nausea and/or vomiting that is sometimes from nose. triggered by sensory stimuli associated with chemotherapy administration. 1 2. Types of Vomiting Features of Cancer Chemotherapy induced nausea and 2.1. Vomiting centre vomiting: The chemoreceptor trigger zone in the Area postrema plays 1.
    [Show full text]
  • NIH Public Access Author Manuscript Neuroscience
    NIH Public Access Author Manuscript Neuroscience. Author manuscript; available in PMC 2016 January 22. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Neuroscience. 2015 January 22; 0: 775–797. doi:10.1016/j.neuroscience.2014.10.044. Early-life Exposure to the SSRI Paroxetine Exacerbates Depression-like Behavior in Anxiety/Depression-prone rats Matthew E. Glover1, Phyllis C. Pugh1, Nateka L. Jackson1, Joshua L. Cohen1, Andrew D. Fant2, Huda Akil3, and Sarah M. Clinton1,§ 1Department of Psychiatry and Behavioral Neurobiology, University of Alabama-Birmingham, USA 2Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA 3Molecular and Behavioral Neuroscience Institute, University of Michigan, USA Abstract Selective serotonin reuptake inhibitor (SSRI) antidepressants are the mainstay treatment for the 10–20% of pregnant and postpartum women who suffer major depression, but the effects of SSRIs on their children’s developing brain and later emotional health are poorly understood. SSRI use during pregnancy can elicit antidepressant withdrawal in newborns and increase toddlers’ anxiety and social avoidance. In rodents, perinatal SSRI exposure increases adult depression- and anxiety- like behavior, although certain individuals are more vulnerable to these effects than others. Our study establishes a rodent model of individual differences in susceptibility to perinatal SSRI exposure, utilizing selectively-bred Low Responder (bLR) and High Responder (bHR) rats that were previously bred for high versus low behavioral response to novelty. Pregnant bHR/bLR females were chronically treated with the SSRI paroxetine (10 mg/kg/day p.o.) to examine its effects on offspring’s emotional behavior and gene expression in the developing brain.
    [Show full text]
  • Rolapitant Improves Quality of Life of Patients Receiving Highly Or Moderately Emetogenic Chemotherapy
    Support Care Cancer (2017) 25:85–92 DOI 10.1007/s00520-016-3388-7 ORIGINAL ARTICLE Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy Martin Chasen1 & Laszlo Urban2 & Ian Schnadig3 & Bernardo Rapoport4 & Dan Powers5 & Sujata Arora5 & Rudolph Navari6 & Lee Schwartzberg7 & Cesare Gridelli8 Received: 4 April 2016 /Accepted: 17 August 2016 /Published online: 24 August 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract with no impact on daily life (total score >108 [range 18–126]). Purpose Addition of rolapitant to standard antiemetic therapy We performed a prespecified analysis of the MEC/ improved protection against chemotherapy-induced nausea anthracycline-cyclophosphamide (AC) study and a post hoc and vomiting (CINV) in phase 3 trials of patients receiving analysis of two pooled cisplatin-based HEC studies. highly emetogenic chemotherapy (HEC) or moderately Results In the pooled HEC studies, rolapitant significantly emetogenic chemotherapy (MEC). Here, we assessed the im- improved the FLIE total score (114.5 vs 109.3, p<0.001), pact of CINV on the daily lives of patients receiving HEC or nausea score (55.3 vs 53.5, p<0.05), and vomiting score MEC using the Functional Living Index-Emesis (FLIE). (59.2 vs 55.8, p<0.001) versus control; similar results were Methods In three double-blind phase 3 studies, patients re- observed in the MEC/AC study for FLIE total score (112.7 vs ceiving HEC or MEC were randomized 1:1 to receive oral 108.6, p < 0.001), nausea score (54.1 vs 52.3, p<0.05), and rolapitant 180 mg or placebo prior to chemotherapy plus 5- vomiting score (58.6 vs 56.3, p < 0.001).
    [Show full text]
  • HHS Template for Reports, with Instructions
    Texas Vendor Drug Program 1.1 Drug Use Criteria: Substance P/Neurokinin1 Receptor Antagonists Publication History 1. Developed December 2003. 2. Revised September 2020; September 2018; September 2016; May 2015; August 2013; June 2013; September 2011; October 2009; February 2006; January 2006. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document. Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage. Prepared by: • Drug Information Service, UT Health San Antonio. • The College of Pharmacy, The University of Texas at Austin. 1 1 Dosage [*] Current therapies for chemotherapy-induced nausea/vomiting (CINV) and post- operative nausea and vomiting (PONV) target corticosteroid, dopamine, and serotonin (5-HT3) receptors. In the central nervous system, tachykinins and neurokinins play a role in some autonomic reflexes and behaviors. Aprepitant is a selective human substance P/neurokinin 1 (NK1) antagonist with a high affinity for NK1 receptors and little, if any, attraction for corticosteroid, dopamine, or 5-HT3 receptors. Rolapitant (Varubi®), the newest substance P/NK1 antagonist, is FDA- approved to prevent delayed CINV with initial and repeat chemotherapy courses including, but not limited to, highly emetogenic chemotherapy in adults. Combination therapy including netupitant, a substance P/NK1 antagonist and palonosetron, a selective 5-HT3 receptor antagonist (Akynzeo®), is now available to prevent acute and delayed CINV with initial and repeat chemotherapy courses including, but not limited to, highly emetogenic chemotherapy in adults.
    [Show full text]
  • EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011)
    EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011) 912 final COMMISSION STAFF WORKING PAPER on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Accompanying the document REPORT FROM THE COMMISSION on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances {COM(2011) 430 final} EN EN TABLE OF CONTENTS 1. Introduction...................................................................................................................3 2. Methodology.................................................................................................................4 3. Key findings from the 2002 evaluation of the Joint Action on synthetic drugs ...........5 4. Overview of notifications, types of substances and trends at EU level 2005-2010......7 5. Other EU legislation relevant for the regulation of new psychoactive substances.....12 6. Functioning of the Council Decision on new psychoactive substances .....................16 7. Findings of the survey among Member States............................................................17 7.1. Assessment of the Council Decision ..........................................................................17 7.2. Stages in the functioning of the Council Decision .....................................................18 7.3. National responses to new psychoactive substances ..................................................20
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Safety of HTX-019 (Intravenous Aprepitant) and Fosaprepitant in Healthy Subjects
    Research Article For reprint orders, please contact: [email protected] Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects Tom Ottoboni*,1, Michael Lauw2, Mary Rose Keller2,MattCravets3, Kimberly Manhard4, Neil Clendeninn‡,5 & Barry Quart6 1Pharmaceutical & Translational Sciences, Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, CA 92121, USA 2Clinical Operations, Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, CA 92121, USA 3Biometrics, Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, CA 92121, USA 4Drug Development, Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, CA 92121, USA 5Clinical, Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, CA 92121, USA 6Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, CA 92121, USA *Author for correspondence: Tel.: +1650 261 3003; Fax: +1650 365 6490; [email protected] ‡Employee at time of study, currently consultant to Heron Therapeutics, Inc. Aim: Evaluate safety of HTX-019, a novel polysorbate 80– and synthetic surfactant-free intravenous for- mulation of neurokinin 1 receptor antagonist aprepitant for chemotherapy-induced nausea and vom- iting. Methods: Two open-label, randomized, two-way crossover studies evaluated treatment-emergent adverse events (TEAEs) in 200 healthy subjects. Subjects received HTX-019 130 mg (30-min infusion) and fosaprepitant 150 mg (20- or 30-min infusion), with ≥7-day washout between doses. Results: Less than or equal to 30 min after start of infusion, TEAEs occurred in 5 (3%) HTX-019 and 30 (15%) fosaprepitant re- cipients. No HTX-019 recipients had infusion-site adverse events, versus 15 (8%) fosaprepitant recipients.
    [Show full text]
  • Vaginal Administration of Contraceptives
    Scientia Pharmaceutica Review Vaginal Administration of Contraceptives Esmat Jalalvandi 1,*, Hafez Jafari 2 , Christiani A. Amorim 3 , Denise Freitas Siqueira Petri 4 , Lei Nie 5,* and Amin Shavandi 2,* 1 School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK 2 BioMatter Unit, École Polytechnique de Bruxelles, Université Libre de Bruxelles, Avenue F.D. Roosevelt, 50-CP 165/61, 1050 Brussels, Belgium; [email protected] 3 Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium; [email protected] 4 Fundamental Chemistry Department, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, São Paulo 05508-000, Brazil; [email protected] 5 College of Life Sciences, Xinyang Normal University, Xinyang 464000, China * Correspondence: [email protected] (E.J.); [email protected] (L.N.); [email protected] (A.S.); Tel.: +32-2-650-3681 (A.S.) Abstract: While contraceptive drugs have enabled many people to decide when they want to have a baby, more than 100 million unintended pregnancies each year in the world may indicate the contraceptive requirement of many people has not been well addressed yet. The vagina is a well- established and practical route for the delivery of various pharmacological molecules, including contraceptives. This review aims to present an overview of different contraceptive methods focusing on the vaginal route of delivery for contraceptives, including current developments, discussing the potentials and limitations of the modern methods, designs, and how well each method performs for delivering the contraceptives and preventing pregnancy.
    [Show full text]